The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
OPKO Health (OPK) released its Q1 2026 financial results, reporting a loss per share of $0.07, aligning with analyst estimates. Revenue reached $130.51 million, a 25.7% year-over-year decline driven by a smaller diagnostics base, though performance remains supported by strategic partnerships. Looking ahead, LPL Financial Holdings Inc. (LPLA) is scheduled to report its Q1 2026 results on April 30, 2026, with consensus estimates projecting an EPS of $5.49 and revenue of $4.98 billion, a 34.9% annual increase. Notably, analysts have revised LPLA's EPS estimates downward by 4.3% over the past 30 days. Additionally, Organon (OGN) and Altria (MO) have issued their Q1 2026 earnings reports to evaluate performance against Wall Street expectations. OPKO continues to maintain a robust balance sheet with a current ratio of 3.97 as investors monitor the broader earnings cycle and its impact on long-term profitability.
Sign in to access this content
Sign In